Acro Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 12:36 pm EDT
Share
Acro Biomedical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.2985 million. Net loss was USD 3.93 million. Basic loss per share from continuing operations was USD 0.07.
Acro Biomedical Co., Ltd. is principally engaged in the business is the sale of cordyceps related products. The Company is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The Company's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus, which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The Company is involved in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. It sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.
ACRO BIOMEDICAL CO., LTD. 
